These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16198977)

  • 21. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vascular thrombosis and oral contraceptives].
    Lefèvre D; Mouroziès X; Fontan R; Hammoudi S; Becade P; Mazères F; Bastide G
    Phlebologie; 1987; 40(4):981-6. PubMed ID: 3447202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Migraine and hormonal contraceptives].
    Grässler W; Olthoff KH
    Z Arztl Fortbild (Jena); 1984; 78(6):229-32. PubMed ID: 6203234
    [No Abstract]   [Full Text] [Related]  

  • 25. [Oral contraceptives and thrombocytopenic thrombotic purpura].
    López Izquierdo A; Calvo-Villas JM; Ramírez-Sánchez M; Sicilia Guillén F
    Sangre (Barc); 1999 Oct; 44(5):388-9. PubMed ID: 10618920
    [No Abstract]   [Full Text] [Related]  

  • 26. [Challenges for the current oral hormonal contraception when applied to women with increased risk for ovarian and breast malignancies].
    Usunova I
    Akush Ginekol (Sofiia); 2008; 47 Suppl 2():46-7. PubMed ID: 19504708
    [No Abstract]   [Full Text] [Related]  

  • 27. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral contraceptives, hormone therapy and cardiovascular risk.
    Shapiro S
    Climacteric; 2008 Oct; 11(5):355-63. PubMed ID: 18781479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Peroral hormonal contraception and risk of venous thromboembolism].
    Ludka O; Spinar J; Musil V; Pozdísek Z
    Vnitr Lek; 2010 May; 56(5):370-5. PubMed ID: 20578585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Combined hormonal contraception unsuitable together with lamotrigine].
    Lakartidningen; 2010 Oct 27-Nov 2; 107(43):2654. PubMed ID: 21137535
    [No Abstract]   [Full Text] [Related]  

  • 31. [Risks and benefits of hormonal contraception].
    Lähteenmäki P
    Duodecim; 1987; 103(9):525-31. PubMed ID: 3331140
    [No Abstract]   [Full Text] [Related]  

  • 32. [Diffuse symptoms in young women may indicate venous thromboembolism. Important to ask about the use of combined hormonal contraception].
    Milsom I; von Sydow H; Thörn AB; Björkelund C; Odlind V
    Lakartidningen; 2012 Sep 19-26; 109(38):1680-2. PubMed ID: 23094400
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment with oral contraceptives. Swiss consensus conference on frequently discussed questions about hormonal contraception].
    Strobel E
    Fortschr Med; 1992 Jul; 110(20):369-70. PubMed ID: 1521840
    [No Abstract]   [Full Text] [Related]  

  • 34. [Lowering the steroid dose in oral contraception and risk of functional ovarian cysts].
    Mayenga JM; Segard L; Cohen J; Belaïsch-Allart J
    Contracept Fertil Sex; 1995; 23(7-8):439-41. PubMed ID: 7550556
    [No Abstract]   [Full Text] [Related]  

  • 35. Migraine and use of combined hormonal contraceptives: a clinical review.
    MacGregor EA
    J Fam Plann Reprod Health Care; 2007 Jul; 33(3):159-69. PubMed ID: 17609074
    [No Abstract]   [Full Text] [Related]  

  • 36. [Routines for prescription of contraceptives (estrogen+gestagen)].
    Nesheim BI; Bergsjø P
    Tidsskr Nor Laegeforen; 1979 Feb; 99(3):180-1. PubMed ID: 419499
    [No Abstract]   [Full Text] [Related]  

  • 37. [Breast cancer and use of antihypertensive drugs and oral contraceptives: results of a case-control study (author's transl)].
    Clavel F; Lê M; Laplanche A
    Bull Cancer; 1981; 68(5):449-55. PubMed ID: 7332791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug interactions with hormonal contraception.
    Guillebaud J
    J Fam Plann Reprod Health Care; 2005 Oct; 31(4):335-6; author reply 336. PubMed ID: 16274570
    [No Abstract]   [Full Text] [Related]  

  • 39. Estrogen and thromboembolic disorders: should patients stop hormones prior to cosmetic surgery?
    Shiffman MA
    J Womens Health (Larchmt); 2003 Nov; 12(9):853-5; discussion 855. PubMed ID: 14670164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [What does the micropill bring?].
    Mall-Haefeli M
    Ther Umsch; 1986 May; 43(5):365-71. PubMed ID: 2941889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.